Octahydrocurcumin

Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively^[1][2]. In Vivo:Octahydrocurcumin (5-20 mg/kg; i.g.; daily; 7 days) exerts potent dose-dependent anti-HCC activity in H22 ascites tumor-bearing mice, with 20 mg/kg OHC increasing survival by 78.98%, reducing ascites volume and cancer cell viability, inducing apoptosis, and modulating mitochondrial pathway-related proteins more effectively than 100 mg/kg curcumin, without immune organ toxicity^[1].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits xylene-induced mouse ear edema, achieving a maximum suppression rate of 70.67% at 40 mg/kg^[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently reduces acetic acid-induced vascular permeability in mice, reaching a 48.0% suppression rate at 40 mg/kg^[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits Carrageenan (HY-125474)-induced mouse paw edema, reduces pro-inflammatory mediator production, selectively suppresses COX-2 expression, and blocks the TAK1-NF-κB pathway^[2].